Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K/mTOR inhibitor BEZ235 against glioblastoma.

Abstract

Glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults. Despite multiple treatment strategies, the prognosis is still poor. This study aimed to evaluate the efficacy of combination treatment of GBM with the histone deacetylase (HDAC) inhibitor panobinostat and dual phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235. GBM cells were exposed to panobinostat and BEZ235 treatment alone or in combination, after which cell viability, proliferation and apoptosis were detected. Furthermore, the inhibitory mechanisms were investigated by Caspase-Glo assay, Western blot and qPCR analysis. We found that combination treatment with panobinostat and BEZ235 synergistically inhibited cell viability, markedly inhibited cell proliferation and induced apoptosis in GBM cells. Mechanistically, cotreatment with panobinostat and BEZ235 increased caspase 3/7 activity, suppressed proliferation- and antiapoptosis-related markers and AKT signaling in GBM cells. Cotreatment with panobinostat and BEZ235 warrants further evaluation in GBM therapy.

• Authors: Wei Meng, Baocheng Wang, Weiwei Mao, Jiajia Wang, Yang Zhao, Qifeng Li, Chenran Zhang, Jie Ma
• Journal: Nagoya journal of medical science (Nagoya J Med Sci) Vol. 81 Issue 1 Pg. 93-102 (Feb 2019) ISSN: 2186-3326 [Electronic] Japan
• PMID: 30962658 (Publication Type: Journal Article)

Chemical References

• Histone Deacetylase Inhibitors
• Imidazoles
• Quinolines
• Panobinostat
• MTOR protein, human
• TOR Serine-Threonine Kinases
• dactolisib

Topics

• Apoptosis (drug effects, genetics)
• Blotting, Western
• Cell Line, Tumor
• Cell Proliferation (drug effects, genetics)
• Cell Survival (drug effects, genetics)
• Drug Synergism
• Glioblastoma (metabolism)
• Histone Deacetylase Inhibitors (pharmacology)
• Humans
• Imidazoles (pharmacology)
• Panobinostat (pharmacology)
• Phosphatidylinositol 3-Kinases (metabolism)
• Quinolines (pharmacology)
• Signal Transduction (drug effects, genetics)
• TOR Serine-Threonine Kinases (metabolism)